2012
Nicorandil Attenuates Monocrotaline-Induced Vascular Endothelial Damage and Pulmonary Arterial Hypertension
Sahara M, Sata M, Morita T, Hirata Y, Nagai R. Nicorandil Attenuates Monocrotaline-Induced Vascular Endothelial Damage and Pulmonary Arterial Hypertension. PLOS ONE 2012, 7: e33367. PMID: 22479390, PMCID: PMC3316574, DOI: 10.1371/journal.pone.0033367.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntihypertensive AgentsApoptosisBlotting, WesternCaspase 3Cells, CulturedDrug Therapy, CombinationEndothelium, VascularEnzyme InhibitorsFamilial Primary Pulmonary HypertensionGlyburideHuman Umbilical Vein Endothelial CellsHumansHypertension, PulmonaryInjections, IntraperitonealMaleMAP Kinase Signaling SystemMonocrotalineNG-Nitroarginine Methyl EsterNicorandilPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktRandom AllocationRatsRats, Sprague-DawleySignal TransductionVentricular PressureConceptsRight ventricular systolic pressurePulmonary arterial hypertensionHuman umbilical vein endothelial cellsVascular endothelial damageMCT injectionArterial hypertensionEndothelial damageNitro-L-arginine methyl esterNitric oxide synthase inhibitorBeneficial effectsEndothelial NOS expressionVentricular systolic pressureVehicle-treated groupChannel blocker glibenclamideOxide synthase inhibitorChannel opener nicorandilSprague-Dawley ratsCaspase-3 expressionAnti-apoptotic effectsUmbilical vein endothelial cellsPromising therapeutic potentialBcl-2 expressionAnti-apoptotic factorsNicorandil administrationVein endothelial cells
2006
New Insights in the Treatment Strategy for Pulmonary Arterial Hypertension
Sahara M, Takahashi T, Imai Y, Nakajima T, Yao A, Morita T, Hirata Y, Nagai R. New Insights in the Treatment Strategy for Pulmonary Arterial Hypertension. Cardiovascular Drugs And Therapy 2006, 20: 377-386. PMID: 17124557, DOI: 10.1007/s10557-006-0498-3.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAnticoagulantsAntihypertensive AgentsCalcium Channel BlockersDiureticsDrug Therapy, CombinationHumansHypertension, PulmonaryMaleMiddle AgedNicorandilNitric Oxide DonorsOxygen Inhalation TherapyPhosphodiesterase InhibitorsPiperazinesPurinesPyridazinesSildenafil CitrateSulfonesVasodilator AgentsConceptsPulmonary arterial hypertensionFunctional class IVArterial hypertensionNew York Heart Association functional class IVNYHA functional class IVPhosphodiesterase type 5 inhibitorsClass IVIntravenous prostacyclin therapyOral combination therapyRational pharmacological therapyFirst-line therapyPhosphodiesterase type 3 inhibitorPrimary pulmonary hypertensionEndothelin receptor antagonistsCurrent treatment optionsCalcium channel blockersLong-term efficacyType 5 inhibitorsNovel therapeutic approachesLong-term survivalProstacyclin therapyExercise tolerancePulmonary hypertensionMale patientsPharmacological therapy